
---
title: '君实生物今年拟申报广谱新冠中和抗体临床，覆盖德尔塔等变异株'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=793'
author: 证券时报网
comments: false
date: Fri, 06 Aug 2021 21:11:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=793'
---

<div>   
<p>证券时报e公司讯，8月6日，记者从上海<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SS688180" style="color: #2f67d1;text-decoration: none;" code="688180" target="_blank">君实生物</a>医药科技股份有限公司（<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SS688180" style="color: #2f67d1;text-decoration: none;" code="688180" target="_blank">君实生物</a>，688180.SH）获悉，该公司将于今年下半年申报广谱新冠中和抗体新药的临床申请，新药可覆盖德尔塔等多种变异株。(澎湃新闻)</p>
                  
</div>
            